Erasca's Eras-801 for Treatment of Brain Tumors Gets FDA Orphan Drug Designation
By Sabela Ojea
Erasca said Thursday that its Eras-801 medication aimed at treating brain tumors was granted Orphan Drug Designation by the U.S. Food and Drug Administration.
Shares rise 3.4% to $2.75 in after-hours trading.
The clinical-stage oncology company said Eras-801 has been designated to treat aggressive brain tumors such as Glioblastoma.
While orphan-drug status doesn't guarantee FDA approval as a treatment for a rare disease, it is a prerequisite for getting incentives such as tax breaks and marketing exclusivity if the agency approves the drug for that purpose.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 22, 2023 16:41 ET (20:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?